Showing 4301-4310 of 9938 results for "".
- FDA Grants Fast Track Designation for Union’s Oral Orismilast for Moderate to Severe HShttps://practicaldermatology.com/news/fda-grants-fast-track-designation-for-unions-oral-orismilast-for-the-treatment-of-moderate-to-severe-hs/2461493/The US Food and Drug Administration (FDA) has granted Fast Track designation to oral orismilast for the treatment of moderate to severe hidradenitis suppurativa (HS). The FDA's Fast Track designation is intended to facilitate the development and review of drug candidates that treat
- Sofwave Scores FDA Clearance to Improve Cellulitehttps://practicaldermatology.com/news/sofwave-scores-fda-clearance-to-improve-cellulite/2461488/Sofwave’s SUPERB technology is now US Food and Drug Administration (FDA)-cleared to improve the appearance of cellulite. SUPERB (Synchronous Ultrasound Parallel Beam) technology couples cooled transducers directly to the epidermis, creating a unique 3D arr
- Regenerative Medicine in Action: Scars Faded Using Transplanted Hair Follicleshttps://practicaldermatology.com/news/regenerative-medicine-in-action-scars-faded-using-transplanted-hair-follicles/2461486/Skin scars began to behave more like uninjured skin after they were treated with hair follicle transplants in a small new study. The scarred skin harboured new cells and blood vessels, remodelled collagen to restore healthy patterns, and even expressed genes found in healthy unscarred s
- Crown Taps Shellie Hammock as EVP and General Counselhttps://practicaldermatology.com/news/crown-taps-shellie-hammock-as-evp-and-general-counsel/2461483/Shellie Hammock is Crown Laboratory’s new Executive Vice President and General Counsel and will hold a position on the Executive Leadership Team and Global Strategic Planning Team. This is a new position within Crown that will provide strategic legal oversight across al
- Journey Medical Corporation Shares Positive Comparative Pharmacokinetic Data for DFD-29 for Rosaceahttps://practicaldermatology.com/news/journey-medical-corporation-shares-positive-comparative-pharmacokinetic-data-for-dfd-29-for-rosacea/2461473/Journey Medical Corporation shared positive PK comparability data of DFD-29 and key updates on the progress of its pivotal Phase 3 clinical study of DFD-29 for the treatment of papulopustular rosacea in collaboration with Dr. Reddy’s Laboratories Ltd. The PK study was designed as
- UCB's Bimekizumab Performs Well in Hidradenitis Suppurativahttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-hidradenitis-suppurativa/2461464/UCB’s bimekizumab may be a promising treatment approach in adults with moderate to severe hidradenitis suppurativa, according to topline results from two Phase 3 studies, BE HEARD I and BE HEARD II. The positive results from these two studies will form the basis of global reg
- Almirall Appoints Mercedes Diz as VP, Corporate Strategyhttps://practicaldermatology.com/news/almirall-appoints-mercedes-diz-as-vp-corporate-strategy/2461449/Almirall named Mercedes Diz as its VP Corporate Strategy. Diz will also join Almirall's Management Board of Directors, effective December 1. Diz joined Almirall in 2002 and, since 2021, has held the position of Senior Director of Corporate Str
- FDA Clears the Accure Laser System for the Treatment of Mild to Severe Inflammatory Acne Vulgarishttps://practicaldermatology.com/news/fda-clears-the-accure-laser-system-for-the-treatment-of-mild-to-severe-inflammatory-acne-vulgaris/2461439/The FDA has cleared Accure Acne Inc's Accure Laser System to treat mild to severe inflammatory acne vulgaris. The Accure Laser System builds upon the unique selectivity of the 1726nm laser wavelength, adding proprietary technology to precisely control thermal gradient depth. This technology b
- Nu Skin Launches ageLOC LumiSpa iOhttps://practicaldermatology.com/news/nu-skin-launches-ageloc-lumispa-io/2461437/Nu Skin Enterprises is introducing ageLOC LumiSpa iO system, a smart skin treatment and cleansing device with a connected, immersive experience. Featuring Nu Skin's patented micropulse technology, the new ageLOC LumiSpa iO system offers customized treatment options, intel
- Castle's DecisionDx-SCC Provides Clarity in Assessing Risk SCC Spread in Challenging Staging Situationshttps://practicaldermatology.com/news/castles-decisiondx-scc-provides-clarity-in-assessing-risk-scc-spread-in-challenging-staging-situations/2461436/Castle Biosciences, Inc.’s DecisionDx-SCC test provides objective, independent and significant risk-stratification for cutaneous squamous cell carcinoma (cSCC) tumors with uncertainty in differentiation status. The data were shared in an oral presentation given at the Americ